Sign up to get updates from us
Lowering your LDL levels—so-called “bad cholesterol”—can save your life: an irrefutable observation made possible by the advent of statins. The good news is that we have statins by the bucket-full; however, the bad news is that not everyone can tolerate statins (>20%) or they can’t hit LDL-lowering targets with a statin alone. Enter Nexletol (bempedoic acid) and Nexlizet (bempedoic acid plus ezetimibe) for use alone or in combination with a statin. What’s the global market opportunity for these newly approved agents? (Hint: it’s huge). Esperion’s CEO, Sheldon Koenig tells you exactly how Esperion's discoveries will improve on lipid-lowering treatments, as well as bridge a market gap.
